André T et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: The GERCOR NEONIPIGA phase II study. J Clin Oncol 2023;41(2):255-65. Abstract

Elimova E et al. Zanidatamab + chemotherapy as first line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA). Gastrointestinal Cancers Symposium 2023;Abstract 347.

Goetze TO et al. Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab-based therapy: Final results of the phase II RE-ExPEL study. Gastrointestinal Cancers Symposium 2023;Abstract 359.

Janjigian YY et al. Nivolumab (NIVO) plus chemotherapy (chemo) vs chemotherapy as first-line (1L) treatment for advanced gastric cancer/gastroesophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649. Gastrointestinal Cancers Symposium 2023;Abstract 291.

Janjigian YY et al. Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses. AACR 2022;Abstract CT023.

Janjigian YY et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: Initial findings of the global phase 3 KEYNOTE-811 study. ESMO GI 2021;Abstract LBA4.

Kato K et al. Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (ipi) vs chemotherapy as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648. Gastrointestinal Cancers Symposium 2023;Abstract 290.

Kelly RJ et al. Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577. ASCO 2021;Abstract 4003.

Ku G et al. Updated analysis of DESINTY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen. ESMO 2023;Abstract 1205MO.

Lorenzen S et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – Results from the phase II RAMIRIS study of the German Gastric Cancer Study Group at AIO. Eur J Cancer 2022;165:48-57. Abstract

Manji GA et al. Phase II clinical trial of perioperative pembrolizumab and chemotherapy followed by adjuvant pembrolizumab for resectable gastric/GEJ adenocarcinoma. AACR 2022;Abstract CT009.

Metges J-P et al. First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study. Gastrointestinal Cancers Symposium 2022;Abstract 241.

Moehler MH et al. Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma. Gastrointestinal Cancers Symposium 2023;Abstract 286.

Rah SY et al. Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction cancer: Phase 3 KEYNOTE-859 study. ESMO 2023;Abstract VP1-2023.

Shitara K et al. Zolbetuximab + mFOLFOX6 as 1L treatment for patients with CLDN18.2+/HER2- locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from SPOTLIGHT. Gastrointestinal Cancers Symposium 2023;Abstract LBA292.

Terashima M et al. ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer. ASCO 2023;Abstract 4000.

Xu J et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): A global, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2023;24(5):483-95. Abstract

Xu R-H et al. Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW. ASCO Plenary Series 2023;Abstract 405736.

Yamaguchi K et al. Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naïve patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: Exploratory cohort results in a phase II trial. J Clin Oncol 2023;41(4):816-25. Abstract

Yamaguachi K et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01). Gastrointestinal Cancers Symposium 2022;Abstract 242.